Roche files Avastin in Europe for glioblastoma
Roche is looking for expanded approval in Europe of its blockbuster Avastin for the treatment of the most aggressive type of brain cancer.
Read MoreAuthor: Kevin Grogan
NiCox stock rises as naproxcinod Phase III analysis impresses
Shares in NicOx are on the rise after the French biotechnology firm presented a pooled analysis of late-stage data which shows that its investigational osteoarthritis treatment naproxcinod significantly reduces blood pressure among patients compared to the non-steroidal anti-inflammatory drug naproxen.
Read MoreB-MS to reduce workforce by an additional 10%
Bristol-Myers Squibb has revealed that it is going to cut an extra 10% of its global workforce by 2010, an expansion of a previously-announced cost-cutting plan.
Read MoreGSK signs potential $810 million pact with Dynavax
GlaxoSmithKline has linked up with the USA’s Dynavax Technologies Corp to develop treatments for immuno-inflammatory diseases.
Read MoreElan and Biogen report another PML case in Tysabri patient
Having just announced that it was cutting jobs to concentrate on promoting Tysabri in Crohn’s disease, Elan Corp and partner Biogen Idec have revealed yet another new case of progressive multifocal leukoencephalopathy in a multiple sclerosis patient being treated with the drug.
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
